Table 3.
Modification of the piperidine amide of 2.
![]() | |||
|---|---|---|---|
| No | R | IC50 (μM)a | CC50 (μM)b |
| 224 | ![]() |
0.53 ± 0.08 | 65.0 |
| 17 | ![]() |
>50 | >50 |
| 18 | ![]() |
>50 | >50 |
| 19 | ![]() |
17.6c | 66.7c |
| 20 | ![]() |
24.7 ± 3.5 | 77.3 |
| 21 | ![]() |
24.4 ± 4.0 | 78.0 |
| 22 | ![]() |
3.9 ± 0.4 | 74.2 |
| 23 | ![]() |
>50 | >50 |
| 2424 | ![]() |
1.6 ± 0.8 | 47.9 |
| 25 | ![]() |
24.4 ± 6.3 | 61.0 |
| 26 | ![]() |
24.6 ± 1.6 | >100 |
| 27 | ![]() |
0.96 ± 0.06 | 50.9 |
| 28 | ![]() |
10.9 ± 0.6 | 56.5 |
| 29 | ![]() |
0.49 ± 0.09 | 41.1 |
Inhibition of luciferase expression in WEEV replicon assay.
Cell viability determined by the MTT reduction assay. Values are mean of at least n=3 independent experiments.
Value is n=1 experiment.














